NXS · ASX

Next Science Ltd (ASX:NXS)

AU$0.12

 0.0 (0.0%)
ASX:Live
20/12/2024 04:10:10 PM
Hammer Bullish HALO Ords HALO Consensus Value GROWTH AUS Big Candle +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NXS Overview

NXS Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Strong

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About NXS

Website

Next Science Ltd

Telephone

61.2.9188.7772

Address

Level 14 264-278 George Street Australia Square Sydney, New South Wales (NSW) 2000

Description

Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. It operates through the North America, Australia and New Zealand geographical segments. The company was founded by Matthew Myntti on October 20, 2017 and is headquartered in Sydney, Australia.

NXS Price Chart

Key Stats

Market Cap

AU$35.06M

PE

9.50

EV/EBITDA

0.0

Dividends Overview

DIV Yield

.0%

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.11 - 0.5

Trade Value (12mth)

US$5,852.00

1 week

-7.69%

1 month

-11.11%

YTD

-66.2%

1 year

-61.9%

All time high

4.73

Key Fundamentals

EPS 3 yr Growth

9.30%

EBITDA Margin

-67.20%

Operating Cashflow

-$15m

Free Cash Flow Return

-137.20%

ROIC

-148.30%

Interest Coverage

-19.60

Quick Ratio

3.50

Other Data

Shares on Issue (Fully Dilluted)

292m

HALO Sector

Healthcare

Next Company Report Date

26-Feb-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

NXS Announcements

Latest Announcements

Date Announcements

28 October 24

Publication of XPERIENCE study showing 0% infection rate

×

Publication of XPERIENCE study showing 0% infection rate

24 October 24

NXS Presentation - Wilsons Drug & Device Conference

×

NXS Presentation - Wilsons Drug & Device Conference

22 October 24

Appendix 4C & Quarterly Activity Report - 30 September 2024

×

Appendix 4C & Quarterly Activity Report - 30 September 2024

16 October 24

Notice of 3Q FY24 Result and Investor Webinar

×

Notice of 3Q FY24 Result and Investor Webinar

20 September 24

Notification of cessation of securities - NXS

×

Notification of cessation of securities - NXS

20 September 24

Notification regarding unquoted securities - NXS

×

Notification regarding unquoted securities - NXS

20 September 24

Notification regarding unquoted securities - NXS

×

Notification regarding unquoted securities - NXS

20 September 24

Appendix 3Y - I.V. Hall

×

Appendix 3Y - I.V. Hall

30 August 24

Half Year Report & Appendix 4D

×

Half Year Report & Appendix 4D

30 August 24

Next Science reports 1H FY24 Result

×

Next Science reports 1H FY24 Result

30 August 24

1H FY24 Result Presentation

×

1H FY24 Result Presentation

22 August 24

Next Science revises FY24 guidance

×

Next Science revises FY24 guidance

26 July 24

Notice of 1H FY24 Result and Investor Webinar

×

Notice of 1H FY24 Result and Investor Webinar

26 July 24

Appendix 3Y - I.V. Hall

×

Appendix 3Y - I.V. Hall

26 July 24

Cleansing notice

×

Cleansing notice

25 July 24

Appendix 4C & Quarterly Activity Report - 30 June 2024

×

Appendix 4C & Quarterly Activity Report - 30 June 2024

25 July 24

Notification regarding unquoted securities - NXS

×

Notification regarding unquoted securities - NXS

25 July 24

Application for quotation of securities - NXS

×

Application for quotation of securities - NXS

17 July 24

Next Science enters into US$5m unsecured loan facility

×

Next Science enters into US$5m unsecured loan facility

17 July 24

Proposed issue of securities - NXS

×

Proposed issue of securities - NXS

10 July 24

Notice of 2Q FY24 Result and Investor Webinar

×

Notice of 2Q FY24 Result and Investor Webinar

08 July 24

Becoming a substantial holder

×

Becoming a substantial holder

14 June 24

Notification regarding unquoted securities - NXS

×

Notification regarding unquoted securities - NXS

14 June 24

Appendix 3Y - I.V. Hall

×

Appendix 3Y - I.V. Hall

07 May 24

Appendix 3Z - D Spira

×

Appendix 3Z - D Spira

NXS Fundamentals

Per Share Records

Historical data

Forecast data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.06 -0.07 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.06 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock 25.3 -26.8 -15.4 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A 9.5 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.05 -0.05 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.06 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock 22.2 -26.5 7.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -4.6 -11.9 -29.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.05 0.04 0.04 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.04 0.03 0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -51.3 -37.0 36.6 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 197 210 234 Lock Lock Lock
Basic m Lock Lock Lock Lock 197 210 234 Lock Lock Lock

Financial Records

Historical data

Forecast data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 9 12 22 Lock Lock Lock
     Growth % Lock Lock Lock Lock 160.0 30.9 89.4 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 16 21 31 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 6 8 15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 177.6 34.2 83.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock 68.7 70.5 68.2 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 31 30 32 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -9 -12 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 25.5 -33.8 -26.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -98.5 -100.7 -67.2 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -10 -13 -16 Lock Lock Lock
     Growth % Lock Lock Lock Lock 23.3 -32.1 -26.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -107.4 -108.4 -72.3 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -9 -13 -16 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -9 -13 -16 Lock Lock Lock
     Growth % Lock Lock Lock Lock 21.5 -35.7 -28.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -104.5 -108.3 -73.4 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -8 -12 -15 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 0 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 0 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 10 20 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -8 -12 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 30.7 -41.3 -29.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.9 -1.0 -0.7 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 7 5 9 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 14 12 18 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -7 -4 -8 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 3 4 5 Lock Lock Lock
Equity $m Lock Lock Lock Lock 11 8 12 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 11 9 14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -42.8 -17.3 50.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -68.2 -101.8 -90.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -84.1 -154.4 -130.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -63.9 -127.0 -142.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -62.9 -129.6 -148.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -55.6 -120.5 -137.2 Lock Lock Lock

Ratios Records

Historical data

Forecast data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -535.2 -412.5 -19.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.8 0.3 0.6 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -63.8 -47.4 -66.7 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 6.6 3.2 3.6 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 5.7 2.8 3.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 72.0 61.9 66.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -536.6 -452.2 -392.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 4.2 8.9 8.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 2.2 3.0 9.1 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 1.0 2.0 2.3 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 13.5 17.3 6.2 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.7 0.9 1.2 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.7 0.9 1.2 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -104.5 -108.3 -73.4 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -68.2 -101.8 -90.9 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -68.2 -101.8 -90.9 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.5 1.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -84.1 -154.4 -130.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -84.1 -154.4 -130.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 169.1 122.4 40.2 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 85.9 40.9 42.7 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 255.0 163.3 82.9 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 124.1 196.4 87.5 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 130.9 -33.0 -4.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.0%

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NXS Shortsell

Frequently Asked Questions

The current share price of Next Science Ltd (NXS:ASX) is AU$0.12.
The 52-week high share price for Next Science Ltd (NXS:ASX) is AU$0.50.
The 52-week low share price for Next Science Ltd (NXS:ASX)? is AU$0.11.
The current TTM dividend payout for Next Science Ltd (NXS:ASX) is 0.00.
Next Science Ltd (NXS:ASX) does not pay a dividend.
Next Science Ltd (NXS:ASX) does not offer franking credits.
Next Science Ltd (NXS:ASX) is classified in the Healthcare.
The current P/E ratio for Next Science Ltd (NXS:ASX) is 9.50.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.